secwatch / observer

8-K filed March 27, 2025, 7:59 PM ET ticker BCLI CIK 0001137883

regulatory confidence high sentiment neutral materiality 0.65

Nasdaq panel grants Brainstorm Cell Therapeutics extension to June 30, 2025 to regain listing compliance

BRAINSTORM CELL THERAPEUTICS INC.

Nasdaq Hearings Panel granted extension to June 30, 2025 to regain compliance with $35M minimum Market Value of Listed Securities.
Company plans to meet $2.5M minimum stockholders' equity requirement as alternative to MVLS compliance.
Extension conditioned on demonstrating compliance with Nasdaq Listing Rule 5550 and progress in capital raising.
Company cannot assure success in raising capital or satisfying equity requirement by the extension date.
Plan presented at February 25, 2025 hearing; capital raising activities are a key component.

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-028529
form_type: 8-K
ticker: BCLI
cik: 0001137883
company_name: BRAINSTORM CELL THERAPEUTICS INC.
filed_at: 2025-03-27T23:59:59+00:00
discovered_at: 2026-05-14T18:03:03.022168+00:00
generated_at: 2026-05-24T03:39:38.865719+00:00
sec_items: ["8.01"]
event_type: regulatory
sentiment: neutral
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-028529
json_url: https://secwatch.observer/filing/0001104659-25-028529.json
markdown_url: https://secwatch.observer/filing/0001104659-25-028529.md
text_url: https://secwatch.observer/filing/0001104659-25-028529.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465925028529/0001104659-25-028529-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465925028529/tm2510584d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

LESL

Leslie's regains Nasdaq compliance for minimum market value of publicly held shares

Leslie's, Inc. June 1, 2026, 4:28 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

VYGR

FDA clears IND for VY1706, Voyager's tau-silencing gene therapy for Alzheimer's

Voyager Therapeutics, Inc. June 1, 2026, 8:00 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

EXFY

Expensify regains Nasdaq minimum bid price compliance

Expensify, Inc. May 29, 2026, 5:15 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SLXN

Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted

Silexion Therapeutics Corp May 29, 2026, 7:00 AM ET regulatory Items 3.03, 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing

RICHTECH ROBOTICS INC. May 28, 2026, 4:49 PM ET regulatory Items 3.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

MNKD

FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29

MANNKIND CORP May 28, 2026, 8:37 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SNAL

Snail receives Nasdaq extension to Sept 22, 2026 to regain listing compliance

Snail, Inc. May 27, 2026, 4:25 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

JAGX

Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027

Jaguar Health, Inc. May 27, 2026, 9:10 AM ET regulatory Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001104659-25-028529

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.